# Virion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virion-therapeutics

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.viriontx.com
- Total disclosed funding: $4M
- Latest round: Angel (Sep 4, 2018)
- Investors on record: 6

## About

Virion Therapeutics, LLC is dedicated to developing innovative T cell-based immunotherapies targeting cancer and chronic infectious diseases, utilizing advanced genetically encoded checkpoint modifiers.Virion Therapeutics, LLC, founded in 2018 and headquartered in Newark, US, focuses on T cell-based immunotherapies. The company has engaged in 2 deals, with the most recent deal being a VENTURE DEBT funding round of USD 0.25 mn on October 28, 2019, raising a total of USD 4.05 mn. The CEO, Andrew Luber, leads the firm, guiding its strategic direction.Virion Therapeutics specializes in developing innovative T cell-based immunotherapies aimed at treating cancer and chronic infectious diseases. Central to their offerings is the use of genetically encoded checkpoint modifiers (CPMs) that enhance and broaden CD8+ T cell responses. Their lead product, VRON-0200, is currently in the first-in-human study phase, with enrollment initiated in Q3 2023. The company's therapies utilize their proprietary VIACT™ platform, delivering optimized target antigens through heterologous chimpanzee adenoviral vectors, targeting markets in North America and Europe.Virion Therapeutics generates revenue through clinical trials and partnerships with healthcare institutions, collaborating with research hospitals and clinical trial networks. Their revenue structure is based on research agreements or grants, with potential future sales of approved therapies. The flagship product, VRON-0200, alongside other therapies from the VIACT™ platform, is poised for market entry upon successful clinical outcomes and regulatory approvals.Virion Therapeutics plans to advance its product pipeline with VRON-0200 expected to enter the market following successful clinical trials. The recent VENTURE DEBT funding of USD 0.25 mn will support these initiatives and aid in expanding their operations into targeted markets across North America and Europe. The company is focused on enhancing its clinical trial capabilities and securing additional partnerships to facilitate growth.

## Funding rounds

- Angel, Sep 4, 2018, $4M — Keiretsu Forum, Alliance of Angels, Life Science Angels, Inc., Robin Hood Ventures, Mid Atlantic Bio Angels, Crimson Peak

## Investors

- Keiretsu Forum — Angel
- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Angel
- Life Science Angels, Inc. — Angel
- Robin Hood Ventures (https://capitalatlas.ai/funds/robin-hood-ventures) — Angel
- Mid Atlantic Bio Angels (https://capitalatlas.ai/funds/mid-atlantic-bio-angels) — Angel
- Crimson Peak — Angel